
Sign up to save your podcasts
Or


What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
By HBR Presents / Brian Kenny4.5
190190 ratings
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.

406 Listeners

1,471 Listeners

105 Listeners

145 Listeners

1,099 Listeners

3,976 Listeners

1,377 Listeners

746 Listeners

106 Listeners

170 Listeners

38 Listeners

837 Listeners

677 Listeners

218 Listeners

79 Listeners

170 Listeners

82 Listeners